

Intestinal Adaptations after Bariatric Surgery: Consequences on Glucose Homeostasis

Jean-Baptiste Cavin, André Bado, Maude Le Gall

▶ To cite this version:

Jean-Baptiste Cavin, André Bado, Maude Le Gall. Intestinal Adaptations after Bariatric Surgery: Consequences on Glucose Homeostasis. Trends in Endocrinology and Metabolism = Trends in Endocrinology & Metabolism , 2017, [Epub ahead of print]. 10.1016/j.tem.2017.01.002 . inserm-01480079

HAL Id: inserm-01480079 https://inserm.hal.science/inserm-01480079

Submitted on 1 Mar 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Intestinal Adaptations after Bariatric Surgery: Consequences on Glucose Homeostasis

Jean-Baptiste Cavin, André Bado, Maude Le Gall1#

▶ To cite this version:

Jean-Baptiste Cavin, André Bado, Maude Le Gall 1#. Intestinal Adaptations after Bariatric Surgery: Consequences on Glucose Homeostasis. Trends in Endocrinology & Metabolism, 2017, <10.1016/j.tem.2017.01.002.>. <inserm-01480079>

HAL Id: inserm-01480079 http://www.hal.inserm.fr/inserm-01480079

Submitted on 1 Mar 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Intestinal adaptations after bariatric surgery: consequences on

2 glucose homeostasis

- 3
- 4 Jean-Baptiste CAVIN¹, André BADO¹ and Maude LE GALL^{1#}
- ⁵ ¹ Inserm UMR 1149, UFR de Médecine Paris Diderot, Université Paris
- 6 Diderot, Sorbonne Paris Cité, DHU Unity APHP, F-75890 Paris France
- 7
- 8 # Correspondance: maude.le-gall@inserm.fr
- 9 http://www.cri1149.fr/
- 10

11 ABSTRACT

The gastrointestinal (GI) tract can play a direct role in glucose homeostasis by 12 modulating the digestion and absorption of carbohydrates and by producing the 13 incretin hormones. In recent years, numerous studies have focused on intestinal 14 adaptation following bariatric surgeries. Changes in the number of incretin-15 (GLP-1, GIP) producing cells have been reported which could result in the 16 modified hormonal response seen after surgery. Additionally, the rate of 17 absorption and the intestinal regions exposed to sugars may affect the time 18 course of appearance of glucose in the blood. This reviewgives new insightsinto 19 the direct role of the GI tract in the metabolic outcomes of bariatric surgery, in 20 the context of glucose homeostasis. 21

22

23 **KEYWORDS**

- 24 Intestine, Roux-en-Y gastric bypass, Vertical sleeve gastrectomy,
- 25 Nutrientflow,Enteroendocrine cells,Glucose transport
- 26

28 Introduction

Bariatric surgeries were originally developed to treat patients with severe 29 obesity; they were initially recommended for patients with morbid obesity (body 30 mass index (BMI) > 40 kg/m2) or severe obesity (BMI 35.0-39.9 kg/m2) when 31 they exhibited at least one comorbidity that had the potential of being improved 32 by the intervention [1,2]. Today, the two most commonly performed bariatric 33 surgeries worldwide are the Roux-en-Y gastric bypass (RYGB, Figure 1A) and 34 the vertical sleeve gastrectomy (VSG, Figure 1B)[3]. Bariatric surgeries have 35 consistently resulted in significantimprovements on obesity-associated 36 metabolic diseases such as type2 diabetes. This resulted in new 37 recommendations proposing that surgery should be considered for moderately 38 obese diabetic patients (BMI 30.0-34.9 kg/m2) if hyperglycemia is inadequately 39 controlled despite optimal treatment with medication[4,5]. These new 40 recommendationshave already been adopted by several medical societies all 41 around the world and should further increase the number of operated patients in 42 the near future. Understanding these surgeries is thus of major clinical and 43 societal importance. 44

The fact that the GItract is the direct target of bariatric procedures potentially makes it a key player, although so far underestimated, in the metabolic changes observed after surgery. Indeed, the GI tract can play a direct role in glucose homeostasis by modulating gastric emptying, the digestion of carbohydrates and absorption of glucose during meals, and also by secreting a set of hormones, including incretins that regulate the release of insulin[6].

In this review, we will outline the GI-dependent mechanisms responsible for the alteration of gut hormone secretion after surgery. Then, we will discuss how intestinal glucose transport (thepassage of glucose from the intestinal lumen to the blood compartment through intestinal epithelial cells), and intestinal glucose

metabolism are modified after RYGB and VSG, and describe how these changes
can affect glucose homeostasis.

57

58 Altered gut hormone secretion

After bariatric surgeries, changes in the fasting and postprandial secretion of gut-derived hormones aresignificant and varied and depend on the type of GI reconstruction [7,8]. These changes are suggested to be key players in the increased postprandial secretion of insulin and improved insulin sensitivity that is reported after bariatric surgery.

64 Glucagon-like peptide 1 (GLP-1)

GLP-1 is an incretin hormone produced by enteroendocrinecells scattered 65 throughout the intestinal epithelium. The density of these GLP-1 secreting cells 66 increases across a proximal to distal gradient. GLP-1 increases insulin release 67 and decreases glucagon production, delays gastric emptying and intestinal transit 68 and reduces meal size[9]. Although fasting concentrations of GLP-1 do not 69 change markedly after bariatric surgery, postprandial levels of GLP-1 have been 70 shown to increase following most, if not all, bariatric procedures[10–13]. 71 However, studies designed to evaluate the influence of GLP-1 per se on glucose 72 regulation and weight loss, have produced varied results. Mice with genetic loss-73 of-function of the GLP-1 receptor respond normally to VSG [14] and RYGB 74 [15] in terms of both weight loss and improvements in glucose regulation. 75 Conversely, specific deletion of the GLP-1 receptor in beta cells was shown to 76 prevent the improvement of glucose tolerance in VSG-operated mice [16]. 77 Together these studies indicate that GLP-1 alone cannot account for the overall 78 metabolic effect of these two surgeries but may contribute to the altered 79 postprandial glycemic response after VSG in mice. In humans, GLP-1 80 antagonists (exendin-9-39) failed to impair the otherwise improved glucose 81 tolerance after VSG [17] and had only modest effects on glycemic response after 82 RYGB [18,19]. 83

84 *Glucose-dependent insulinotropic polypeptide (GIP)*

GIP is another incretin hormonesecreted by enteroendocrinecells located mostly 85 in the duodenum and proximal jejunum and released in response to nutrients 86 (notably lipids) [9].GIP promotes the conversion of glucose to fatty acids and 87 their storage in adipose tissues[20]. While some studies report similar 88 enhancements of GIP secretion following RYGB and VSG surgery [21], others 89 have documented GIP levels to be unchanged [10,22]or reduced 90 [23,24] following RYGB surgery. Although not yet formally demonstrated, it is 91 possible that since GIP is produced by cells of the proximal intestine, 92 differences in the length of the intestinal limb bypassed by the surgery could 93 differentially affect meal-induced GIP secretion in patients. Moreover, the 94 presence or the absence of type-2 diabetes in patients before bariatric 95 surgerymightaffect he alteration of GIP secretion after surgery [25,26]. A recent 96 study investigated the combined and separate effects of endogenously secreted 97 GLP-1 and GIP on glucose tolerance after RYGB [27]. GLP-1 increased insulin 98 and attenuated glucagon secretion in the postprandial state, whereas 99 amplification of the GIP signal aggravated postprandial hyperglucagonemia and 100 did not contribute to the improved glucose tolerance[27]. The role of GIP in 101 102 theimproved glucose tolerance following RYGBis still an open questionand also remains to be addressed in detail in the context of VSG. 103

104 *Ghrelin*

Ghrelin is an orexigenic hormone produced mainly in the stomach and 105 duodenum that exerts gluco-regulatory functions[28]. Resection of the fundic 106 region in VSG leads to a decrease in ghrelin-expressing cells and concomitant 107 ghrelin-circulating levels in rats [29,30] and humans[11,31,32]. Body weight 108 and glucose tolerance measurements after VSG, however, showed similar results 109 in ghrelin-deficient and in wild-type mice [33]. Moreover, while postprandial 110 ghrelin levels are reduced after VSG[11,31,32], they have been reported to 111 either decrease[34], increase [32,35]or remainunchanged[11,36]after RYGB 112

113 compared to obese patients.Post-operativemodifications of ghrelin levels after

surgery are, therefore, unlikely to determine metabolic improvement.

115 Other digestive hormones

Hormones, such ascholecystokinin[10], PYY[37] and others [7], have also been 116 found to be modulated after some bariatric procedures andhave thus been 117 proposed as important factors contributing to the post-surgery metabolic 118 improvement. Hormonal changes are certainly involved in the positive outcomes 119 of surgery, but all simplistic views aiming to identify "the" determinant 120 hormone responsible for the beneficial effect of bariatric surgeries are probably 121 shortsighted and futile, sinceGI surgerieslead to a profound alteration of the 122 entire gut's hormonal response, following a meal. After surgery, a new 123 homeostatic state is instituted and thus hormone levels should be considered in 124 relation to each other rather than compared to their pre-operative values. For 125 instance, physiologically, glucagon secretion decreases after a meal, but it has 126 been shown that postprandial glucagon release is increased following RYGB 127 and VSG compared to pre-operative states [21,38]. Interestingly, one study 128 reported that GIP, GLP-1, and GLP-2 differently affect glucagon responses to 129 orally ingested glucose in patients with diabetes [39].Indeed, in non-operated 130 diabetic patients, intravenous infusion of GIP increased the glucagon response 131 and thus counteracted the reduction of glucagon secretion associated with 132 intravenous infusion of GLP-1. Since postprandial levels of GLP-1 and GIP are 133 modified after bariatric surgery, these hormonal interactions could explain how 134 postprandial glucagon levels are increased. Understanding how all these 135 hormonal signals act together to mediate the effects of surgery is an important 136 but ambitious research goal, particularly considering that we are far from 137 understanding how they are integrated together, even in physiological 138 conditions. 139

The origin of these modified hormonal secretions is still debated. Historically, 141 altered nutrient flow, either by foregut exclusionor by accelerated hindgut 142 delivery of nutrients, was considered responsible for the improved hormonal 143 responseand the success of derivative procedures like RYGB[40]. The modified 144 postprandial hormonal response observed after VSG, a purely gastric surgery in 145 which the food path is not modified, however, has somewhat weakened these 146 assumptions. More recent studies have nevertheless revealed that gastric 147 emptying rates were indeed very rapid after VSG [41–43]. 148

149

Accelerated nutrient flow and increasedintestinal surface

151 exposure

GI remodeling leads to a drastic acceleration of food arrival in the intestine, by pyloric exclusion after RYGB [12,44]and also by an increase in gastric emptying rate after VSG[42,43]. Increasing evidence shows that the modified dynamics of the nutrient flow is likely to contribute both the modified glycemic response to a meal andthe concomitant altered gut hormone secretion in patients.

The total intestinal surface that is almost immediately exposed to a liquid meal 158 is drastically different between operated and control individuals, and affects the 159 entry of glucose into the blood[44]. A study, using radiolabeled tracer, found 160 that only five minutes after a nutrient gavage, the stomachs of RYGB and VSG 161 rats were completely emptied, whereas only 6.1% of the nutrient mixture had 162 emptied from sham animals [41]. The accelerated gastric emptying and food 163 delivery to the intestine increases the total intestinal surface exposed to the 164 luminal content. This could have a direct effect on the rate of glucose entry into 165 the blood during a sugar-rich meal. Indeed, this hypothesis was illustrated by a 166 recent study using multiple intestinal clamp sites in minipigs with RYGB 167 [45]. The study demonstrated a direct relationship between the exposed intestinal 168 area and the transfer of glucose to the blood. More interestingly, the insulin 169

response and secretion of GLP-1 significantly increased only when the total 170 intestinal surface was accessible by the liquid meal. Even if one cannot 171 discriminate whether the stimulation of the distal intestine by the meal or the 172 increase in blood glucose *per se* is responsible for the hormonal response, these 173 experiments suggest that the hormonal response to a meal after RYGB is highly 174 dependent on the altered nutrient flow caused by GI reconstruction. 175 Two human studies confirmed the role of altered nutrient flow in the hormonal 176 response observed after surgery[12,44]. In the first, RYGB patients received 177 either a glucose drink or the same solution infused into the proximal Roux limb 178 at 4 kcal/min, a rate equivalent to physiologic gastric emptying[44]. Blood 179 glucose, insulin, glucagon, GIP and GLP-1 were then measured during the 180 test. The glycemic response was delayed in RYGB patients receiving the solution 181 at 4 kcal/min compared to when the same solution was received orally. 182 Moreover, the infusedpatients' hormonal responses were similar to those 183 observed in non-operated subjects receiving the oral drink, thus supporting the 184 effect of rapid nutrient exposure on the exaggerated incretin responses. The 185 second study evaluated GI motility with a scintigraphic technique, andgut 186 hormone secretion in RYGB patients [12]. The authors found a statistically 187 significant association between gastric pouch emptying and hormone responses 188 during a multiple meal test. In contrast, no relation was found between gut 189 hormone release and gastric pouch emptying when they used a solid 190 radiolabeled marker, further strengthening the role of rapid nutrient flow in 191 hormone secretion, sincetransit of solids is much slower than liquids. 192 Interestingly, a study in rats showed that intestinal infusion of a glucose solution 193 at an identical rate led to a greater GLP-1 secretion in VSG rats relative to sham-194 operated controls [41]. This suggests the existence of delivery-independent 195 mechanisms that alter the gut hormonal response, at least in VSG rats. 196 In summary, the altered glycemic and hormonal response to a liquid meal in 197 RYGB and VSG patients is likely to be mediated by the accelerated nutrient 198

199 flow after both surgeries, which increases the surface of contact between the 200 meal and the intestine. However, it is worth noting that amixed meal test may

201 differ in many ways with the daily diet pattern of patients[46] and that

thehormonal responses observed experimentally may not occur during smallsolid meals[47,48].

The altered nutrient flow and subsequent modified nutritional stimulation of the intestine after surgery could cause the intestinal adaptation that in turn might affect hormonal secretion and the glycemic response to a meal.

207

208 Intestinal adaptation and enteroendocrine cell number

Due to the difficulty of directly studying the GI tract of bariatric patients, most 209 of the studies aiming to describe intestinal adaptations after RYGB or VSG 210 procedureshave been conducted in experimental models such as rodents. In 211 2009, Stearns et al. were the first to report changes in intestinal structure and 212 function in a rat model of RYGB [49]. They showed an increased villus size and 213 crypt depth in the Roux limb and common limb of operated rats. This 214 hyperplasia has been confirmed and further characterized by several subsequent 215 studies [50–55]. 216

217

An important consequence of Roux limb overgrowth after RYGB is an increase in the total number of enteroendocrine cells, including GLP-1-, GIP-,CCK- and PYY-producing cells within the intestinal mucosa[52,54,56,57]. This adaptation was reported in both human and rodent RYGB subjects and could contribute to the modified hormonal profileafter surgery. Whether the increased number of enteroendocrine cellsdue to Roux limb overgrowth is associated with an additionalincrease in their density, is still a matter of debate[54,57,58].

To date, no study has directly investigated intestinal adaptation after VSG in 226 humans. However, two recent reports using rat models of VSG described an 227 absence of hypertrophy of the jejunum mucosa after this surgery [54,59]. 228 The distribution of enteroendocrine cells producing GLP-1 was also examinedin 229 these studies but contradictory results were obtained. The first study reported 230 that GLP-1 cell numbers were not modified at 3 month post-VSG [59].In 231 contrast, a second studyreported an increase in the number and density of GLP-1 232 cells14 days after surgery[54]. It remains to be determined whether this 233 discrepancy results from the different time pointstaken foranalysis, or 234 differences in other variables such as post-operative diet or surgical 235 techniques. An increase in the density of GLP-1 cellswould, however, be a 236 reasonable explanation for the higher delivery-independent GLP-1 secretion 237 observed after VSGin rats [21,37]. 238

239

Whether modified numbers of enteroendocrine cells actually affect the release of
gut hormone after surgery remains to be determined. An increase in hormone
productionby or an exacerbated nutrient sensitivity of the enteroendocrine cells
after the surgery could also be involved. Assaying the sensitivity of
enteroendocrine cells to nutrients before and after surgery will be a challenging
task in the future but development of enteroids from human biopsies couldoffer
a unique opportunity to evaluate it[60,61].

247

248 Intestinal adaptation and glucose transport

The idea that bariatric surgeries could lead to alterations in intestinal glucose transport has been the subject of several studies. To be absorbed by the intestine, polysaccharides must be hydrolyzed into their monosaccharide components (glucose, galactose and fructose) by saccharidases. Glucose and galactose are transported across the apical membrane into the enterocyte by the sodium/glucose cotransporter 1 (SGLT1)[62], whereas fructose is taken up by

the fructose transporter 5 (GLUT5)[63]. Monosaccharides are partly 255 metabolized in the enterocytes but most of them exit the cellsvia glucose 256 transporter 2 (GLUT2) in the basolateral membrane, a process that delivers them 257 to the blood before reaching the liver for further metabolism and regulation of 258 glucose production[64]. During sugar-rich meals or in the case of insulin 259 resistance, monosaccharide absorption might be exacerbated after translocation 260 of GLUT2 to the apical membrane [65]. Thus, the appearance of glucose in the 261 blood follows a time course that is affected by the intestinal surface exposed to 262 nutrients, but also by the number of functional enterocytes and the expression of 263 their glucose transporters. 264

Molecular analyses have produced heterogeneous results regarding the 265 expression pattern of intestinal sugar transporters after RYGB in 266 rats[49,51,53,54].SGLT1, GLUT2 and GLUT5 mRNA or protein levels were 267 reported to be increased[51], decreased [49,51,53]or not modified[54][53] in the 268 alimentary Roux limb of RYGB animals, compared to the jejunum of sham 269 animals. The heterogeneity of these molecular analyses could be due to 270 experimental differences such as different postoperative time points, variable 271 surgical procedures or pre- and post-operative diets. Additionally, the presence of 272 273 different steps in the adaptive process[54], or alterations in expression levels following diurnal rhythms [49] also likely influence the results. One study 274 reported no difference for SGLT1, GLUT2 or GLUT5 mRNA levels between 275 the Roux limb, the biliopancreatic limb or the common limbof a RYGB minipig 276 model [45]. In humans, increased mRNA expression of SGLT1 and GLUT2has 277 been reported more than a year after surgery[66]. Thus species-related 278 differences might also exist. 279

It is worth highlighting that the activity of SGLT1 does not always correlate with
its mRNA expression [49,54]. The growth of the intestinal mucosa, following
RYGB, and therefore the increased numbers of enterocytes could affect the total
absorptive capacity of the intestine, beyond the expression of sugar transporters.

In fact, it is hard to demonstrate the relationship between transporter expression and the glycemic response to an oral glucose tolerance test *in vivo*. Accordingly, differences in the glycemic response of rats between 14 and 40 days post-RYGB have not been observed despitesignificant variation in the expression of their intestinal sugar transporters [30]. Direct assessments of intestinal glucose transport capacity before and after surgeryare,therefore,still needed to evaluate the existing functional changes.

Ex vivo, glucose transport can be measured by radioactive methods with isolated 291 intestinal segments from rats that have undergone bariatric surgery. Entry of 292 glucose into the enterocytes (from the mucosal or serosal side) is referred to 293 asintestinal glucose uptake but is often misnamed as intestinal glucose transport, 294 which is actually the passage of glucose from the intestinal lumen to the blood 295 compartment through enterocytes. Of note, in a recent study, no alteration in 296 glucose transport in the Roux limb of RYGB rats compared to the jejunum of 297 sham ratswas observed, whereas glucose uptake wasmarkedly increased in 298 RYGB ratsregardless of the entry site (mucosal or serosal side) [54]. After 299 RYGB, some studies report a reduction in intestinal glucose 300 uptake[45,49]whereas others report no changes [54,67]. It has also been reported 301 302 that RYGB may abolish the diurnal rhythm associated SGLT1-mediated glucose uptake, with a 63% reduction specifically prior to the onset of feeding [49]. 303 304 Finally, a study in humans reported that RYGB was followed by an increase in SGLT-1 expression and showed a positive association between SGLT-1 305 expression and glucose absorption [66]. Once again, the methods used to 306 evaluate the glucose uptake, the intestinal segments, and the exact time-points at 307 which measurements were made after surgery differed widely among studies, 308 309 probably contributing to the heterogeneity of the results. To the best of our knowledge, only one group has evaluated glucose transport 310 and uptake after VSG [54]. In this study, glucose transport from the luminal to 311

the serosal side was markedly decreased in the jejunum of VSG rats, compared

to sham-operated rats. Expression of the sugar transporters SGLT1, GLUT2 or 313 GLUT5 did not reflect the modification in intestinal transport capacity. The 314 mechanism of this regulation is still unknown, but VSG could improve glucose 315 tolerance by delaying the entry of alimentary glucose. This would be in 316 agreement with the delayed glycemic response observed after an oral load of 317 glucose in rats [54]or in VSGsubjectscomparedto RYGBsubjects[68]. 318 It is difficult to transpose these *ex vivo* findings upon what actually happens 319 during a glucose gavage or a meal, since the dynamic aspect of nutrient flow is 320 lost. In addition, whilst intestinal glucose transport may be reflected by the early 321 slope of an oral tolerance test, glucose clearance after the peak is the reflection 322 of glucose disposal by peripheral organs such as liver, muscles and adipose 323 tissue but also, as described below, the intestine itself. 324

325

326 Intestinal adaptation and glucose disposal

It has been shown recently that hyperplasia in the Roux limb after RYGB is 327 associated with a reprogramming of glucose metabolism towards increased 328 329 intestinal glucose uptake and consumption by intestinal cells [53,54]. The remodeled intestine could thus increase wholebody glucose disposal and 330 contribute to the glucose lowering effect of derivative bariatric procedures. 331 The reprogramming of glucose metabolism is characterized by increased mRNA 332 and protein levels of enzymes involved in glycolysis, and by the appearance of 333 the glucose transporter GLUT1 at the basolateral membrane of enterocytes 334 [53,59,54]. The GLUT1 transporter is widely expressed during development but 335 its expression is decreased in adults and becomes very low in mature jejunum 336 [69]. The overexpression of intestinal GLUT1 after RYGB might be a 337 consequence of the increased energy demand to support the intestinal 338 hyperplasia that occurs very early after surgery. Accordingly, there is no 339 reprogramming of glucose metabolism and no overexpression of GLUT1 in the 340 jejunum of VSG-operated rats that does not display any hyperplasia [54,59]. 341

In vivo, using positron emission tomography-computed tomography (PET-CT) 342 scanning and intravenous administration of [¹⁸F]-FDG, it has been demonstrated 343 that RYGB surgery increases intestinal glucose disposal in rats [53]. Similarly, 344 another study reported increased metabolic activity in the Roux limb of 345 humansfollowing bariatric surgery using the same techniques[54]. 346 Considering the contribution of increased intestinal glucose disposal to the 347 glucose lowering effect of RYGB surgery, a study on rats using PET-CT 348 scanning reported a 90% higher [¹⁸F]-FDG uptake by the intestine of RYGB-349 treated rats and a 30% reduction in [¹⁸F]-FDG signal in the blood, compared to 350 sham animals^[53]. This suggests that intestinal glucose utilization is key to the 351 improvement of wholebody glucose disposal in rats. To date, intestinal blood 352 glucose disposal has not been quantified in human patients, but a recent study 353 measured GI retention and presumably metabolism of ingested glucose in obese 354 subjects before and after RYGB [70]. Using a mixed meal containing labeled 355 [^{6,6-2}H2]-glucose, the authors demonstrated that GI clearance of ingested glucose 356 is increased after RYGB surgery. However, the difference effected by the 357 bariatric procedure was low (from $10\% \pm 8\%$ before to $15\% \pm 9\%$ after surgery), 358 showing that intestinal glucose diversion during meals is not likely to largely 359 contribute to the postprandial improvement in glycemic control. 360 Studies directly measuring the intestinal clearance of intravenously 361 administrated glucose are needed to evaluate whether the reprogramming of 362 glucose metabolism and subsequent increase in intestinal glucose disposal 363 makes a real contribution to the glucose lowering effect of RYGB surgery in 364 humans. 365

366

367 **Concluding Remarks and Future Perspectives**

Glucose excursion after a meal depends onintestinal transport of glucose to the
blood, secretion of gut hormones and glucose handling by peripheral organs.
The remodeledGI tract after bariatric surgery plays a major role in altering all

these processes. Complementing the associated accelerated nutrient flow and 371 increased intestinal surface exposure, the two main types of bariatric surgeries, 372 RYGB and VSG, differently alter gut morphology, gut hormone secretions, and 373 intestinal glucose transport and metabolism (Key Figure) and these factors may 374 all contribute to glucose homeostasis. The biggest challenge now is to evaluate 375 the relative contribution of all these mechanisms (**Outstanding questions box**) 376 and to find a way to recapitulate the important ones in non-surgical or less 377 invasive treatments. 378

379

380 FIGURES AND KEY FIGURE

Figure 1: Two common types of bariatric surgeries

(A) The Roux-en-Y gastric bypass (RYGB) consists of creating a small 382 gastricpouch below the esophagus (25-50mL in humans) that is connected 383 directly to the middle portion of the jejunum, bypassing the rest of the stomach, 384 the pylorus and the upper portion of the small intestine (duodenum and proximal 385 jejunum), which is anastomosed distally. The operation creates three 386 anatomically distinct gut segments: an alimentary limb (or Roux limb), which 387 receives only undigested food (red arrows); a biliopancreatic limb, which drains 388 gastric secretions, bile and pancreatic enzymes (blue arrows); and a common 389 limb that connects the two aforementioned limbs together. This operation is very 390 efficient, with an important and sustained weight loss accompanied by a 391 reduction in obesity-associated comorbidities such as hypertension, 392 hyperlipidemia and type 2 diabetes in most patients. (B) The vertical sleeve 393 gastrectomy (VSG) involves a longitudinal resection of the stomach starting 394 from the antrum and ending at the fundus close to the cardia; the remaining 395 volume of the gastric compartment is about 150 mL in humans. This 396 intervention has been proven to be an effective procedure at middle term with an 397 important weight loss accompanied by a reduction in obesity-associated 398

comorbidities such as hypertension, hyperlipidemia and type 2 diabetes in manypatients.

401

402 **Figure 2, Key Figure**: Differential intestinal adaptations after RYGB versus

403 VSG and their putative contributions to the resulting altered hormone 404 secretion and improved glucose tolerance.

Both bariatric surgeries reduce the transit time of the meal and increase the 405 exposure of the intestinal mucosa that acts to modify secretion by enteroencrine 406 cells and also glucose entry. In response to RYGB, the Roux limb becomes 407 hyperplasic, with the number of incretin secreting cells increasing. Additionally, 408 a shift in glucose metabolism increases the intestinal glucose consumption.In 409 response to VSG, despite no intestinal hyperplasia, the number of GLP-1 410 positive cells mayincrease due to increased cell density. Moreover, studies in 411 rats suggest that glucose transport from the lumen to the blood decreases 412 delaying alimentary glucose absorption. To date, no study has directly 413 investigated intestinal adaptation after VSG in humans. 414

416 **REFERENCES**

- 417
- Hubbard, V. and Hall, W. (1991) Gastrointestinal Surgery for Severe Obesity. *Obes. Surg.* 1, 257–
 265
- 420 2 NIH Conference (1991) Gastrointestinal Surgery for Severe Obesity. Ann. Intern. Med. 115, 956
- 421 3 Angrisani, L. et al. (2015) Bariatric Surgery Worldwide 2013. Obes. Surg. 25, 1822–1832
- 4 Rubino, F. *et al.* (2016) Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A
 Joint Statement by International Diabetes Organizations. *Surg. Obes. Relat. Dis. Off. J. Am. Soc.*Bariatr. Surg. 12, 1144–1162
- Rubino, F. *et al.* (2016) Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A
 Joint Statement by International Diabetes Organizations. *Diabetes Care* 39, 861–877
- 427 6 Holst, J.J. *et al.* (2016) Roles of the Gut in Glucose Homeostasis. *Diabetes Care* 39, 884–892
- 428 7 Meek, C.L. *et al.* (2016) The effect of bariatric surgery on gastrointestinal and pancreatic peptide
 429 hormones. *Peptides* 77, 28–37
- 430 8 Sweeney, T.E. and Morton, J.M. (2014) Metabolic surgery: action via hormonal milieu changes,
 431 changes in bile acids or gut microbiota? A summary of the literature. *Best Pract. Res. Clin.*432 *Gastroenterol.* 28, 727–740
- Baggio, L.L. and Drucker, D.J. (2007) Biology of incretins: GLP-1 and GIP. *Gastroenterology* 132,
 2131–2157
- 435 10 Jacobsen, S.H. *et al.* (2012) Changes in gastrointestinal hormone responses, insulin sensitivity,
 436 and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. *Obes. Surg.*437 22, 1084–1096
- 438 11 Yousseif, A. *et al.* (2014) Differential Effects of Laparoscopic Sleeve Gastrectomy and
 439 Laparoscopic Gastric Bypass on Appetite, Circulating Acyl-ghrelin, Peptide YY3-36 and Active GLP440 1 Levels in Non-diabetic Humans. *Obes. Surg.* 24, 241–252
- Dirksen, C. *et al.* (2013) Fast pouch emptying, delayed small intestinal transit, and exaggerated
 gut hormone responses after Roux-en-Y gastric bypass. *Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc.* 25, 346-e255
- Tsoli, M. *et al.* (2013) Hormone changes and diabetes resolution after biliopancreatic diversion
 and laparoscopic sleeve gastrectomy: a comparative prospective study. *Surg. Obes. Relat. Dis. Off. J. Am. Soc. Bariatr. Surg.* 9, 667–677
- 447 14 Wilson-Pérez, H.E. *et al.* (2013) Vertical sleeve gastrectomy is effective in two genetic mouse
 448 models of glucagon-like Peptide 1 receptor deficiency. *Diabetes* 62, 2380–2385
- Mokadem, M. *et al.* (2014) Effects of Roux-en-Y gastric bypass on energy and glucose
 homeostasis are preserved in two mouse models of functional glucagon-like peptide-1
 deficiency. *Mol. Metab.* 3, 191–201
- 452 16 Garibay, D. *et al.* (2016) β-Cell Glucagon-Like Peptide-1 Receptor Contributes to Improved
 453 Glucose Tolerance after Vertical Sleeve Gastrectomy. *Endocrinology* DOI: 10.1210/en.2016-1302
- Jiménez, A. *et al.* (2014) GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese
 subjects with type 2 diabetes. *Diabetes* 63, 3372–3377
- 456 18 Salehi, M. *et al.* (2014) Blockade of glucagon-like peptide 1 receptor corrects postprandial
 457 hypoglycemia after gastric bypass. *Gastroenterology* 146, 669–680.e2
- Shah, M. *et al.* (2014) Contribution of endogenous glucagon-like peptide 1 to glucose metabolism
 after Roux-en-Y gastric bypass. *Diabetes* 63, 483–493
- Kim, S.-J. *et al.* (2007) Activation of lipoprotein lipase by glucose-dependent insulinotropic
 polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase
 cascade. *J. Biol. Chem.* 282, 8557–8567
- Romero, F. *et al.* (2012) Comparable early changes in gastrointestinal hormones after sleeve
 gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. *Surg. Endosc.* 26, 2231–2239
 - 17

466 22 Kashyap, S.R. et al. (2013) Metabolic effects of bariatric surgery in patients with moderate 467 obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with 468 intensive medical treatment. Diabetes Care 36, 2175-2182 469 23 Guidone, C. et al. (2006) Mechanisms of recovery from type 2 diabetes after malabsorptive 470 bariatric surgery. *Diabetes* 55, 2025–2031 471 24 Nosso, G. et al. (2016) Comparative Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy 472 on Glucose Homeostasis and Incretin Hormones in Obese Type 2 Diabetic Patients: A One-Year 473 Prospective Study. Horm. Metab. Res. Horm. Stoffwechselforschung Horm. Metab. 48, 312–317 474 25 Laferrère, B. et al. (2007) Incretin Levels and Effect Are Markedly Enhanced 1 Month After Roux-475 en-Y Gastric Bypass Surgery in Obese Patients With Type 2 Diabetes. Diabetes Care 30, 1709-476 1716 477 26 Mingrone, G. et al. (2009) Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 478 diabetic patients after biliopancreatic diversion. Diabetologia 52, 873-881 479 27 Svane, M.S. et al. (2016) Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-480 en-Y gastric bypass surgery. Am. J. Physiol. Endocrinol. Metab. 310, E505-514 481 28 Delhanty, P.J.D. and van der Lely, A.J. (2011) Ghrelin and glucose homeostasis. Peptides 32, 482 2309-2318 483 29 Arapis, K. et al. (2015) Remodeling of the Residual Gastric Mucosa after Roux-En-Y Gastric Bypass 484 or Vertical Sleeve Gastrectomy in Diet-Induced Obese Rats. PLoS ONE 10, e0121414 30 Rodríguez, A. et al. (2012) Short-term effects of sleeve gastrectomy and caloric restriction on 485 486 blood pressure in diet-induced obese rats. Obes. Surg. 22, 1481-1490 487 31 Goitein, D. et al. (2012) Mapping of ghrelin gene expression and cell distribution in the stomach 488 of morbidly obese patients--a possible guide for efficient sleeve gastrectomy construction. Obes. 489 Surg. 22, 617–622 490 32 Kalinowski, P. et al. (2016) Ghrelin, leptin, and glycemic control after sleeve gastrectomy versus 491 Roux-en-Y gastric bypass-results of a randomized clinical trial. Surg. Obes. Relat. Dis. Off. J. Am. 492 Soc. Bariatr. Surg. DOI: 10.1016/j.soard.2016.08.025 33 Chambers, A.P. et al. (2013) The Effects of Vertical Sleeve Gastrectomy in Rodents Are Ghrelin 493 494 Independent. Gastroenterology 144, 50-52.e5 495 34 Frühbeck, G. et al. (2004) Fasting plasma ghrelin concentrations 6 months after gastric bypass 496 are not determined by weight loss or changes in insulinemia. Obes. Surg. 14, 1208–1215 497 35 Sundbom, M. et al. (2007) Early Changes in Ghrelin following Roux-en-Y Gastric Bypass: Influence 498 of Vagal Nerve Functionality? Obes. Surg. 17, 304-310 499 36 Holdstock, C. et al. (2003) Ghrelin and Adipose Tissue Regulatory Peptides: Effect of Gastric 500 Bypass Surgery in Obese Humans. J. Clin. Endocrinol. Metab. 88, 3177-3183 501 37 Dimitriadis, E. et al. (2013) Alterations in gut hormones after laparoscopic sleeve gastrectomy: a 502 prospective clinical and laboratory investigational study. Ann. Surg. 257, 647–654 503 38 Nannipieri, M. et al. (2013) Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of 504 diabetes remission and role of gut hormones. J. Clin. Endocrinol. Metab. 98, 4391-4399 505 39 Lund, A. et al. (2011) The separate and combined impact of the intestinal hormones, GIP, GLP-1, 506 and GLP-2, on glucagon secretion in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 300, 507 E1038-1046 508 40 Cummings, D.E. et al. (2004) Gastric bypass for obesity: mechanisms of weight loss and diabetes 509 resolution. J. Clin. Endocrinol. Metab. 89, 2608-2615 510 41 Chambers, A.P. et al. (2014) Regulation of gastric emptying rate and its role in nutrient-induced 511 GLP-1 secretion in rats after vertical sleeve gastrectomy. Am. J. Physiol. Endocrinol. Metab. 306, 512 E424-432 513 42 Shah, S. et al. (2010) Prospective controlled study of effect of laparoscopic sleeve gastrectomy on small bowel transit time and gastric emptying half-time in morbidly obese patients with type 514 2 diabetes mellitus. Surg. Obes. Relat. Dis. Off. J. Am. Soc. Bariatr. Surg. 6, 152-157 515 516 43 Braghetto, I. et al. (2009) Scintigraphic Evaluation of Gastric Emptying in Obese Patients 517 Submitted to Sleeve Gastrectomy Compared to Normal Subjects. Obes. Surg. 19, 1515

- 518 44 Nguyen, N.Q. *et al.* (2014) Rapid gastric and intestinal transit is a major determinant of changes
 519 in blood glucose, intestinal hormones, glucose absorption and postprandial symptoms after
 520 gastric bypass. *Obesity* 22, 2003–2009
- 45 Baud, G. *et al.* (2016) Bile Diversion in Roux-en-Y Gastric Bypass Modulates Sodium-Dependent
 Glucose Intestinal Uptake. *Cell Metab.* 23, 547–553
- 46 Laurenius, A. *et al.* (2012) Changes in eating behaviour and meal pattern following Roux-en-Y
 gastric bypass. *Int. J. Obes. 2005* 36, 348–355
- Lee, C.J. *et al.* (2015) Effects of meal composition on postprandial incretin, glucose and insulin
 responses after surgical and medical weight loss. *Obes. Sci. Pract.* 1, 104
- 527 48 Steven, S. *et al.* (2016) Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in
 528 Type 2 Diabetes. *Diabetes Care* 39, 158–165
- Stearns, A.T. *et al.* (2009) Impact of Roux-en-Y gastric bypass surgery on rat intestinal glucose
 transport. *Am. J. Physiol. Gastrointest. Liver Physiol.* 297, G950–G957
- 50 Bueter, M. *et al.* (2010) Gastric bypass increases energy expenditure in rats. *Gastroenterology* 532 138, 1845–1853
- 51 Taqi, E. *et al.* (2010) The influence of nutrients, biliary-pancreatic secretions, and systemic
 trophic hormones on intestinal adaptation in a Roux-en-Y bypass model. *J. Pediatr. Surg.* 45,
 987–995
- 52 Mumphrey, M.B. *et al.* (2013) Roux-en-Y gastric bypass surgery increases number but not density
 of CCK-, GLP-1-, 5-HT-, and neurotensin-expressing enteroendocrine cells in rats.
 Neurogastroenterol. Motil. 25, e70–e79
- 53 Saeidi, N. *et al.* (2013) Reprogramming of intestinal glucose metabolism and glycemic control in 540 rats after gastric bypass. *Science* 341, 406–410
- 54 Cavin, J.-B. *et al.* (2016) Differences in Alimentary Glucose Absorption and Intestinal Disposal of
 542 Blood Glucose After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. *Gastroenterology* 150,
 543 454–464.e9
- 54 55 Cavin, J.-B. *et al.* (2016) Malabsorption and intestinal adaptation after one anastomosis gastric
 bypass compared with Roux-en-Y gastric bypass in rats. *Am. J. Physiol. Gastrointest. Liver Physiol.*546 311, G492-500
- 56 Hansen, C.F. *et al.* (2013) Hypertrophy Dependent Doubling of L-Cells in Roux-en-Y Gastric Bypass
 548 Operated Rats. *PLoS ONE* 8, e65696
- 57 Nergård, B.J. *et al.* (2015) Mucosal glucagon-like peptide-1 and glucose-dependent insulinotropic
 polypeptide cell numbers in the super-obese human foregut after gastric bypass. *Surg. Obes.*551 *Relat. Dis. Off. J. Am. Soc. Bariatr. Surg.* 11, 1237–1246
- 58 Rhee, N.A. *et al.* (2015) Effect of Roux-en-Y gastric bypass on the distribution and hormone
 expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. *Diabetologia* DOI: 10.1007/s00125-015-3696-3
- 55 59 Mumphrey, M.B. *et al.* (2015) Sleeve Gastrectomy Does Not Cause Hypertrophy and
 556 Reprogramming of Intestinal Glucose Metabolism in Rats. *Obes. Surg.* DOI: 10.1007/s11695-014 557 1547-9
- 558 60 Zachos, N.C. *et al.* (2016) Human Enteroids/Colonoids and Intestinal Organoids Functionally 559 Recapitulate Normal Intestinal Physiology and Pathophysiology. *J. Biol. Chem.* 291, 3759–3766
- 560 61 Zietek, T. *et al.* (2015) Intestinal organoids for assessing nutrient transport, sensing and incretin 561 secretion. *Sci. Rep.* 5, 16831
- Lehmann, A. and Hornby, P.J. (2016) Intestinal SGLT1 in metabolic health and disease. *Am. J. Physiol. Gastrointest. Liver Physiol.* 310, G887–G898
- 564 63 Douard, V. and Ferraris, R.P. (2008) Regulation of the fructose transporter GLUT5 in health and
 565 disease. *Am. J. Physiol. Endocrinol. Metab.* 295, E227–E237
- 566 64 Leturque, A. et al. (2012) Carbohydrate intake. Prog. Mol. Biol. Transl. Sci. 108, 113–127
- 567 65 Kellett, G.L. *et al.* (2008) Sugar absorption in the intestine: the role of GLUT2. *Annu. Rev. Nutr.*568 28, 35–54

- 569 66 Nguyen, N.Q. *et al.* (2014) Upregulation of intestinal glucose transporters after Roux-en-Y gastric
 570 bypass to prevent carbohydrate malabsorption. *Obesity* DOI: 10.1002/oby.20829
- 571 67 Bhutta, H.Y. *et al.* (2014) Intestinal sweet-sensing pathways and metabolic changes after Roux-572 en-Y gastric bypass surgery. *Am. J. Physiol. - Gastrointest. Liver Physiol.* 307, G588–G593
- 573 68 Jiménez, A. *et al.* (2015) Remission of type 2 diabetes after Roux-en-Y gastric bypass or sleeve 574 gastrectomy is associated with a distinct glycemic profile. *Ann. Surg.* 261, 316–322
- 575 69 Davidson, N.O. *et al.* (1992) Human intestinal glucose transporter expression and localization of 576 GLUT5. *Am. J. Physiol. - Cell Physiol.* 262, C795–C800
- 577 70 Magkos, F. *et al.* (2016) Effect of Roux-en-Y gastric bypass and laparoscopic adjustable gastric
- banding on gastrointestinal metabolism of ingested glucose. *Am. J. Clin. Nutr.* 103, 61–65
- 579




Figure 1A,B




Figure 2